BridgeBio Pharma, Inc. (BBIO) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for BridgeBio Pharma, Inc. (BBIO): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 52/100 — a percentile rank of BridgeBio Pharma, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.
| Market cap | $13.1B |
| P / S | 18.3× |
| EV / EBITDA | -31.5× |
| Gross margin | 94.4% |
| Operating margin | -69.8% |
| Net margin | -98.5% |
| Return on equity | 27.5% |
| ROIC | 70.2% |
| Revenue growth | 202.4% |
| Debt / equity | -1.0× |
| Dividend yield | 0.0% |
Is BridgeBio Pharma, Inc. overvalued? P/S looks undervalued vs its 5-year range.
Independent of the events above — derived from BridgeBio Pharma, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact